Unique position: With its next-level ability to produce DNA constructs, Stony Brook startup LineaRX is looking to speed up production of critical, anti-cancer chimeric antigen receptor modified T cell (or CAR T) therapies. By GREGORY ZELLER OCTOBER 16, 2018 Marking a big step in the war against cancer, a Stony Brook-based startup has initiated pre-clinical […]
Streamlined manufacturing processes could yield reduced cost and lead times, lessening patient morbidity and mortality through shorter “vein-to-vein” times. [Applied DNA Sciences] By MaryAnn Labant A rapidly emerging immunotherapy approach, adoptive cell transfer (ACT), collects and uses a patient’s own immune cells to treat their cancer. One methodology, Chimeric Antigen Receptor T-Cell (CAR T-cell) therapy, has advanced […]
Applied DNA Subsidiary LineaRx Licenses CAR T Drug Candidate and Initiates Pre-Clinical Development of Non-viral, Plasmid-free CAR T Manufacturing Platform Novel DNA Manufacturing Platform Pioneering a New Generation of Faster, More Affordable CAR T Therapeutics. Offering Available to CRO/CMO Customers STONY BROOK, N.Y., October, 16, 2018 – Applied DNA Sciences Inc. (NASDAQ: APDN) (“Applied DNA” […]
LineaRx offers simplified manufacturing path to RNA Biotherapeutics via linear DNA STONY BROOK N.Y., October 1, 2018 – Applied DNA Sciences Inc. (NASDAQ: APDN) (“Applied DNA), the leader in large-scale PCR-based DNA manufacturing, announced today that LineaRx, Inc. (“LineaRx” ” or the “Company”), its wholly-owned subsidiary focused on next-generation biotherapeutics, has secured multiple new developers […]
Published: Sep 20, 2018 By Mark Terry LineaRx, a subsidiary of Applied DNA Sciences, has entered into a Joint Development Agreement with Takis SRL and Evvivax SLR. They will focus on developing anti-cancer vaccines. Under the terms of the deal, LineaRx and Takis and Evvivax will work together to develop linear DNA expression vectors of two of Takis/Evvivax’s anti-cancer vaccine candidates. They will […]
Collaboration Seeks to Develop PCR-produced Linear DNA as a Safer Expression Vector for Vaccines STONY BROOK N.Y., September 20, 2018 – Applied DNA Sciences Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”) announced today that LineaRx, Inc. (“LineaRx”), its wholly-owned subsidiary focused on next-generation biotherapeutics, has signed a Joint Development Agreement (the “Agreement”) with Takis […]
SEPTEMBER 18, 2018 By GREGORY ZELLER A Stony Brook biotech with a growing international reputation for supply-chain security has spun off a new company focused on DNA modification and production. With an eye on exploding biotherapeutic fields, Stony Brook-based Applied DNA Sciences has spun its DNA-manufacturing business into a new company, LineaRx. Stony Brook-based Applied DNA […]
STONY BROOK N.Y., September 18, 2018 – Applied DNA Sciences Inc., (NASDAQ: APDN, “Applied DNA” or the “Company”), the leader in large-scale PCR-based DNA manufacturing, announced today the formation of LineaRx, Inc., a wholly owned subsidiary. Its purpose is to commercialize the Company’s extensive experience in the design, manufacture and chemical modification of DNA by […]
Applied DNA Presenting Linear DNA for Gene Therapy at Boston Immuno-Oncology Summit High-Expression Amplicons Facilitate Non-Recombinant Gene Therapies Hold the Potential to Serve as an Alternative to Plasmids and Viral Vectors STONY BROOK N.Y., August 27, 2018 – Applied DNA Sciences Inc., (NASDAQ: APDN, “Applied DNA,”), the leader in large-scale PCR-based DNA manufacturing, will present […]